Open AccessPrevalence and clinical significance of BRAF V600E in C hinese patients with lung adenocarcinoma
Author(s) -
Li Zhenxiang,
Jiang Leilei,
Bai Hua,
Wang Zhijie,
Zhao Jun,
Duan Jianchun,
Yang Xiaodan,
An Tongtong,
Wang Jie
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12177
Subject(s) - v600e , medicine , mutation , adenocarcinoma , lung cancer , cancer research , lung , oncogene , oncology , microbiology and biotechnology , cancer , gene , biology , cell cycle , genetics
Background The purpose of this study was to investigate the prevalence, distribution, and prognostic role of v‐raf murine sarcoma viral oncogene homolog B ( BRAF) V600E mutations in C hinese patients with lung adenocarcinoma ( ADC ), and to explore the possibility of BRAF V600E mutation detection in plasma DNA . Methods Data from 190 patients with lung ADCs treated at the P eking U niversity C ancer H ospital from J uly 2011 to M arch 2012 were collected. The amplification refractory mutation system was used for BRAF V600E testing and denaturing high‐performance liquid chromatography for epidermal growth factor receptor ( EGFR) mutation detection. In BRAF V600E ‐mutant cases, paired plasma DNA was tested for mutation status of BRAF V600E and EGFR . The distribution and prognostic role of BRAF V600E mutations were analyzed using SPSS 13.0. Results Among 190 patients with advanced lung ADC , eight (4.2%) cases carried BRAF V600E mutations. V600E mutations presented more frequently in women than in men (6 of 96, 6.3% vs. P = 0.1). BRAF and EGFR mutations were concomitantly presented in three patients. Five of the eight patients with BRAF V600E mutations had matched plasma DNA samples and V600E mutations were found in three plasma samples. Conclusion The prevalence of BRAF V600E mutations in C hinese patients with lung ADC is 4.2%. Circulating plasma DNA may be used for BRAF V600E mutation analysis in lung adenocarcinoma.